Researchers reported updated findings of infigratinib in upper tract urothelial carcinoma and urothelial carcinoma of the bladder, supporting the development of phase III studies in this setting.
Researchers reported on the incidence and outcomes of the SARS-CoV-2 infection, which has been linked to COVID-19, in patients with cancer who were treated at a tertiary cancer institution in Wuhan, China.
Biomarkers of carcinogens, including several with a strong link to bladder cancer, were found to be present in the urine of e-cigarette users.
This study provides the first evidence of the urinary TERT promoter mutations to be used as simple and cost-effective non-invasive biomarkers for the early detection of bladder cancer.
The FDA granted breakthrough therapy designation to enfortumab vedotin based on results from the dose-escalation cohort and expansion cohort A of the phase Ib/II EV-103 trial.
The FDA approved enfortumab vedotin-ejfv (Padcev)—the first drug to treat adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.
The FDA approved pembrolizumab for the treatment of patients with BCG–unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in-situ with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.
The study found that patients who were randomized to receive avelumab and best supportive care lived significantly longer than those who only received best supportive care.
The FDA granted accelerated approval to enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
The anti-PD-1 therapy was recommended as a treatment for certain patients with high-risk, non-muscle invasive bladder cancer.